Flow cytometric analysis of human CD110 expression on human PBMC. Human PBMC were stained with FITC Mouse Anti-Human CD61 Antibody and either Biotin Mouse IgG2a, k Isotype Control (left panel) or SDT Biotin Mouse Anti-Human CD110 Antibody (right panel) at 1.25 μl/test followed by Sav-PE. Flow cytometry and data analysis were performed using Agilent NovoCyte Quanteon and FlowJo™ software.
Product Details
Product Details
Product Specification
| Host | Mouse |
| Antigen | CD110 |
| Synonyms | Thrombopoietin receptor; TPO-R; Myeloproliferative leukemia protein; Proto-oncogene c-Mpl; TPOR; MPL |
| Location | Cell membrane |
| Accession | P40238 |
| Clone Number | S-3014 |
| Antibody Type | Mouse mAb |
| Isotype | IgG2a,k |
| Application | FCM |
| Reactivity | Hu |
| Positive Sample | Human PBMC |
| Purification | Protein A |
| Concentration | 0.2 mg/ml |
| Conjugation | Biotin |
| Physical Appearance | Liquid |
| Storage Buffer | PBS pH7.4, 0.03% Proclin 300 |
| Stability & Storage | 12 months from date of receipt / reconstitution, 2 to 8 °C as supplied |
Dilution
| application | dilution | species |
| FCM | 1.25μl per million cells in 100μl volume | Hu |
Background
CD110, also known as thrombopoietin receptor (TPOR) or MPL (myeloproliferative leukemia protein), is a 635-amino-acid, single-pass type I transmembrane glycoprotein belonging to the hematopoietic cytokine receptor superfamily, whose extracellular N-terminal region binds thrombopoietin (TPO) with high affinity to activate JAK2/STAT, MAPK and PI3K-AKT signaling cascades that drive megakaryocyte proliferation, differentiation and platelet production, while its cytoplasmic C-terminal tail contains critical motifs for internalization and negative feedback regulation; physiologically expressed on hematopoietic stem cells, megakaryocytes, platelets and endothelial cells, CD110 is essential for steady-state and stress hematopoiesis, and genetic alterations—such as MPL W515L/K activating mutations or CALR exon 9 mutations that create neomorphic ligand binding—lead to ligand-independent signaling, constitutive activation and the development of myeloproliferative neoplasms, making CD110 a key diagnostic marker and therapeutic target for small-molecule JAK inhibitors and TPO receptor agonists/antagonists in thrombocytopenias and myelofibrosis.
Picture
Picture
FC
